Question · asked by 1 review
Anti‐VEGF vs no anti‐VEGF: Proportion of participants with relief of pain and resolution of redness, 1 year
- Population
- people with neovascular glaucoma
- Intervention
- Anti‐VEGF
- Comparison
- no anti‐VEGF
- Outcome
- Proportion of participants with relief of pain and resolution of redness, 1 year
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐VEGF vs no anti‐VEGF Proportion of participants with relief of pain and resolution of redness, 1 year · people with neovascular glaucoma The review found no eligible studies for this question. Anti‐vascular endothelial growth factor for neovascular glaucoma (2023) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anti‐vascular endothelial growth factor for neovascular glaucoma 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.